We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Two years ago during a lunch with a group of reporters at the J.P. Morgan confab, then Celgene CEO (now executive chairman) Bob Hugin got my attention with a comment on the importance of neurosciences in the pipeline.